Quality of Life in Pulmonary Arterial Hypertension: Improvement and Maintenance With Bosentan

Journal of Heart and Lung Transplantation

Volumn 26, Issue 2, 2007, Pages 181-187

  Keogh, Anne M ^a   McNeil, Keith D ^b   Wlodarczyk, John ^c   Gabbay, Eli ^d   Williams, Trevor J ^e  

^a ST VINCENT S HOSPITAL   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

^c John Wlodarczyk Consulting Service New Lambton   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

^e ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EMOTIONALITY; FEMALE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; MULTICENTER STUDY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; QUESTIONNAIRE; SOCIAL INTERACTION; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; QUALITY OF LIFE; SULFONAMIDES;

EID: 33846372988     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2006.11.009     Document Type: Article

References (35)

1. British Cardiac Society Guidelines and Medical Practice Committee. Recommendations on the management of pulmonary hypertension in medical practice. Heart 86 suppl I (2001) I1-I13
2. Humbert M.D., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 suppl S (2004) 13S-24S
3. Rubin L.J. Introduction: Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 suppl (2004) 7S-10S
4. Simonneau G., Galiè N., Rubin L.J., et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 43 suppl S (2004) 5S-12S
5. Keogh A.M., McNeil K., Williams T., Gabbay E., and Cleland L.G. Pulmonary arterial hypertension: a new era in management. Med J Austral 178 (2003) 564-567
6. D'Alonzo G.E., Barst R.J., Ayres S.M., et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
7. Koh E.T., Lee, Gladman D.D., and Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheum 35 (1996) 989-993
8. Galiè N., Seeger W., Naeije R., Simonneau G., and Rubin L.J. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43 suppl S (2004) 81S-88S
9. Badesch D.B., Abman S.H., Ahearn G.S., et al. Medical therapy for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 126 suppl (2004) 35S-62S
10. Hoeper M.M., Oudiz R.J., Peacock A., et al. End points and clinical trial designs in pulmonary arterial hypertension. J Am Coll Cardiol 43 suppl S (2004) 48S-55S
11. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-301
12. Olschewski H., Simonneau G., Galiè N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 347 (2002) 322-329
13. Oudiz R.J., Schilz R.J., Barst R.J., et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 126 (2004) 420-427
14. Simonneau G., Barst R.J., Galiè N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 165 (2002) 800-804
15. Sastry B.K., Narasimhan C., Reddy N.K., and Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43 (2004) 114-1153
16. Channick R.N., Sitbon O., Barst R.J., Manes A., and Rubin L.J. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 43 suppl S (2004) 62S-67S
17. Clozel M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: do they explain the long-term benefit?. Ann Med 35 (2003) 1-9
18. Channick R.N., Simonneau G., Sitbon O., et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358 (2001) 1119-1123
19. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
20. Sitbon O., Badesch B.D., Channick R.N., et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 124 (2003) 247-254
21. McLaughlin V., Sitbon O., Badesch B.D., et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 25 (2005) 244-249
22. Galiè N., Hinderliter A.L., Torbicki A., et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 41 (2003) 1380-1386
23. Sitbon O., Gressin V., Speich R., et al. Bosentan for human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 170 (2004) 1212-1217
24. Ware J.E., and Sherbourne C.D. The MOS 36-item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection. Med Care 30 (1992) 473-483
25. Hawthorne G., Richardson J., and Osborne R. The assessment of quality of life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res 8 (1999) 209-224
26. MacHorney C.A., et al. Comparisons of the costs and quality of norms for the SF-36 Health Survey collected by mail versus telephone interview: results from a national survey. Med Care 32 (1994) 551-567
27. Brazier J., Usherwood T., Harper R., and Thomas K. Deriving a preference-based single index from the UK SF-36 Health Survey. J Clin Epidemiol 51 (1998) 1115-1128
28. Brazier J., Roberts J., and Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 21 (2002) 271-292
29. Simpson C.M., Penny D.J., Cochrane A.D., et al. Preliminary experience with bosentan as initial therapy in childhood idiopathic pulmonary arterial hypertension. J Heart Lung Transplant 25 (2006) 469-473
30. Girgis R.E., Mathai S.C., Krishnan J.A., et al. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant 24 (2005) 1626-1631
31. Juenger J., Schellberg D., Kraemer S., et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 87 (2002) 235-241
32. Harper R., Brazier J.E., Waterhouse J.C., et al. Comparison of outcome measures for patients with chronic obstructive pulmonary disease (COPD) in an outpatient setting. Thorax 52 (1997) 879-887
33. Wight J.P., Edwards L., Brazier J., Walters S., Payne J.N., and Brown C.B. The SF-36 as an outcome measure of services for end stage renal failure. Qual Health Care 7 (1998) 209-221
34. Hopman W.M., Towheed T., Anastassiades T., et al. Canadian normative data for the SF-36 health survey. Can Med Assoc J 163 (2000) 265-271
35. Shafazand S., Goldstein M.K., Doyle R.L., Hlatky M.A., and Gould M.K. Health-related quality of life in patients with pulmonary arterial hypertension. Chest 126 (2004) 1452-1459